期刊文献+

初诊前列腺癌骨扫描的必要性分析 被引量:2

Necessity analysis of bone scan in patients with newly diagnosed prostate cancer
原文传递
导出
摘要 目的建立用于预测中国初诊前列腺癌骨转移风险的回归树模型,以减少不必要的骨扫描。方法在2005至2011年复旦大学附属肿瘤医院住院的501例初诊前列腺癌中采用分类及回归树(CART)分析建立Fudan回归树模型,同时验证Briganti回归树模型,并比较两个模型在曲线下面积(AUC)及临床应用价值上的优劣性。结果本组骨转移的发生率为27.5%(138/501)。Fudan回归树模型、Briganti回归树模型及单以骨转移相关症状(SRE)为标准预测骨转移的准确度分别为0.813、0.691及0.645,三者间比较差异有统计学意义(P〈0.05)。当决策阈值概率取值范围为(24.2%,36.8%)时,Fudan回归树模型具有更低的漏诊率及骨扫描过度检查率。结论Fudan回归树模型具有较高的预测价值,同时能减少中国初诊前列腺癌不必要的骨扫描。 Objective To construct a classification and regression tree (CART) to predict the occurrences of bone metastases in patients with newly diagnosed prostate cancer so as to reduce unnecessary bone scans. Methods CART analyses were performed in 501 subjects from 2005 to 2011 of Fudan University Shanghai Cancer Center to establish Fudan CART model and externally validate Briganti's CART model. The both models were compared with regards to the area under the curve (AUC) and their clinical values. Results The rate of bone metastasis was 27.5% ( 138/501 ). The predictive accuracy of Fudan CART model, Briganti's CART model and skeleton-related events (SRE) model was O. 813, 0. 691 and O. 645 respectively. There were statistically significant differences ( P 〈 0. 05 ). Fudan CART model had a lower missed diagnosis and an over-examination rate of bone scan within the probability threshold (Pt) range of 24. 2% to 36. 8%. Conclusion With a higher predictive value, Fudan CART model may be employed to reduce the unnecessary bone scans for Chinese patients with newly diagnosed orostate cancer.
出处 《中华医学杂志》 CAS CSCD 北大核心 2013年第4期248-251,共4页 National Medical Journal of China
基金 国家自然科学基金(30973009、30801149)
关键词 前列腺肿瘤 肿瘤转移 模型 统计学 放射性核素显像 Prostatic neoplasms Neoplasm metastasis Models, statistical Radionuclideimaging
  • 相关文献

参考文献13

  • 1叶定伟.前列腺癌的流行病学和中国的发病趋势[J].中华外科杂志,2006,44(6):362-364. 被引量:168
  • 2叶定伟,沈益君.应重视前列腺癌根治术后并发症的防治[J].中华医学杂志,2011,91(32):2233-2235. 被引量:14
  • 3Citrin DL,Bessent RG,Greig WR. A comparison of the sensitivity and accuracy of the 99Tcm-phosphate bone scan and skeletal radiograph in the diagnosis of bone metastases[J].Clinical Radiology,1977.107-117.
  • 4Rosenthal DI. Radiologic diagnosis of bone metastases[J].Cancer,1997.1595-1607.
  • 5Norgaard M,Jensen AO,Jacobsen JB. Skeletal related events,bone metastasis and survival of prostate cancer:a population based cohort study in Denmark (1999 to 2007)[J].Journal of Urology,2010.162-167.
  • 6Heidenreich A,Bellmunt J,Bolla M. EAU guidelines on prostate cancer.Part 1:screening,diagnosis,and treatment of clinically localised disease[J].European Urology,2011.61-71.
  • 7Briganti A,Passoni N,Ferrari M. When to perform bone scan in patients with newly diagnosed prostate cancer:external validation of the currently available guidelines and proposal of a novel risk stratification tool[J].European Urology,2010.551-558.
  • 8Edge SB,Compton CC. The American Joint Committee on Cancer:the 7th edition of the AJCC cancer staging manual and the future of TNM[J].Annals of Surgical Oncology,2010.1471-1474.
  • 9Vickers AJ,Elkin EB. Decision curve analysis:a novel method for evaluating prediction models[J].Medical Decision Making,2006,(6):565-574.doi:10.1177/0272989X06295361.
  • 10Gallina A,Chun FK,Suardi N. Comparison of stage migration patterns between Europe and the USA:an analysis of 11 350 men treated with radical prostatectomy for prostate cancer[J].British Journal of Urology International,2008.1513-1518.

二级参考文献41

共引文献341

同被引文献29

  • 1曹希亮,高江平,韩刚,唐杰,洪宝发.以前列腺特异抗原水平分组筛查与前列腺穿刺阳性率的关系[J].中华外科杂志,2006,44(6):372-375. 被引量:21
  • 2曹希亮,高江平,许承斌,唐杰,文载律,洪宝发.前列腺穿刺病理组织学类型在不同PSA水平中的分布[J].临床泌尿外科杂志,2007,22(2):109-110. 被引量:10
  • 3Ramankulov A, Lein M, Kristiansen G, et al.Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer[J].Prostate, 2007,67 ( 3 ) : 330-340.
  • 4Gu Z, Thomas G, Yamashiro J, et al.Prostate stem cell antigen (PSCA)expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer[J].Oncogene, 2000,19 ( 10 ) : 1288-1296.
  • 5Morote J, Morin JP, Ors01a A, et al.Prevalence of osteoporosis during long term androgen deprivation therapy in patients with prostate cancer[J].J Urol, 2007,69 ( 2 ) : 500-505.
  • 6Tralongo P, Repetto L, Marl A, et al.Safety of long-term administration of bisphosphonates in elderly cancer patients[J].Oncology,2004,67 ( 3 ) : 112-116.
  • 7Robertson AG, Reed NS, Ralston SH, et al.Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study[J].Journal of Clinical Oncology, 1995,13 ( 9 ) :, 2427-2430.
  • 8Terpos E, Sezer O, Croucher PI, et al.The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network[J].Ann Oncol,2009,20 ( 8 ): 1303-1317.
  • 9American Society of Clinical Oncology.American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer[J].J Clin Oncol, 2011, 29 ( 16 ) : 2293-2296.
  • 10Ferrari-Lacraz S, Ferrari S.Do RANKL inhibitors (denosumab) affect inflammation and immunity?[J]. Osteoporos Int, 2011,22 ( 2 ) : 435-446.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部